Ballentine Partners’s Takeda Pharmaceutical TAK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $743K | Buy |
48,034
+9,656
| +25% | +$149K | 0.01% | 377 |
|
|
2025
Q1 | $571K | Sell |
38,378
-284
| -0.7% | -$4.22K | 0.01% | 407 |
|
|
2024
Q4 | $512K | Buy |
38,662
+7,568
| +24% | +$100K | 0.01% | 418 |
|
|
2024
Q3 | $442K | Buy |
31,094
+10,205
| +49% | +$145K | 0.01% | 453 |
|
|
2024
Q2 | $270K | Buy |
20,889
+4,058
| +24% | +$52.5K | 0.01% | 597 |
|
|
2024
Q1 | $234K | Sell |
16,831
-1,497
| -8% | -$20.8K | ﹤0.01% | 624 |
|
|
2023
Q4 | $262K | Sell |
18,328
-1,640
| -8% | -$23.4K | 0.01% | 544 |
|
|
2023
Q3 | $309K | Buy |
19,968
+6,412
| +47% | +$99.2K | 0.01% | 438 |
|
|
2023
Q2 | $213K | Buy |
13,556
+2,816
| +26% | +$44.2K | ﹤0.01% | 540 |
|
|
2023
Q1 | $177K | Buy |
+10,740
| New | +$177K | ﹤0.01% | 531 |
|
|
2022
Q4 | – | Sell |
-21,416
| Closed | -$278K | – | 528 |
|
|
2022
Q3 | $278K | Sell |
21,416
-22
| -0.1% | -$286 | 0.01% | 360 |
|
|
2022
Q2 | $301K | Sell |
21,438
-6,439
| -23% | -$90.4K | 0.01% | 325 |
|
|
2022
Q1 | $399K | Buy |
27,877
+9,548
| +52% | +$137K | 0.01% | 298 |
|
|
2021
Q4 | $249K | Buy |
+18,329
| New | +$249K | 0.01% | 398 |
|